Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Publisher: La Merie Publishing
Pages: 74
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0016
Release Date: April of 2016

300.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update

This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update

Table of Contents

1. CD19-Targeted Therapeutics:

  • Fc-Engineered CD19-Targeted Antibodies
  • CD19-Targeted Antibody-Drug Conjugates
  • CD19-Targeted Immunotoxin
  • Bispecific, CD19-Targeted and T-Cell Recruiting Monoclonal Antibodies
  • Other CD19-Targeted Bispecific Monoclonal Antibodes
  • Autologous CD19-Targeted Chimeric Antigen Receptor T-Cells
  • Allogeneic CD19-Targeted Chimeric Antigen Receptor T-Cells

2. Corporate CD19-Targeted Therapy Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top